July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
ASCO24 Day 3 Highlights by The Oncology Brothers
Jun 4, 2024, 03:08

ASCO24 Day 3 Highlights by The Oncology Brothers

The Oncology Brothers shared on X:

“1. DB06 TDxD HR+ metastatic breast cancer (mBC)

2. TransMet Liver transplant in metastatic colorectal cancer (mCRC)

3. Collision Surgery/Ablation in mCRC

4. ESOPEC (UpperGI)

5. LAURA Consolidation (mNSCLC)

6. ADRIATIC Durva (LS-SCLC)

7. ReachPC: Palliative Oncology

8. NADINA (Melanoma)

1. DestinyBreast06:

  • Phase III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
  • Majority of HR+ (85%) in this category
  • PFS 13.2 vs 8.1 mos (HR 0.62)
  • AEs: ILD, Fatigue, and Nausea
  • Should I even test for Her2?

Oncology Brothers

2. TransMet:

  • Chemo plus Liver transplant vs Chemo in metastatic liver confined CRC
  • mFU of 59 months, PFS 57% vs 13% (HR: 0.37)
  • OS: 73% vs 9% (HR: 0.16)
  • Importance of Multi-D for liver confined disease

Oncology Brothers

3. COLLISION:

  • Surgery vs Ablation in Liver confined/resectable metastatic CRC
  • No OS difference with thermal ablation or surgery for small Mets
  • Medium size 14mm and 2 lesions
  • Importance of Multi-D but in the right patient, they can stay close to home .

Oncology Brothers

4. ESOPEC:

  • Phase III, perioperative FLOT vs NeoAdj Chemoradiation in adeno-esophageal carcinoma:
  • pCR FLOT (17% vs 10%)
  • Much pCR than original CROSS (23%)
  • 3 yearr OS: 57.4% vs 50.7% (mOS: 66 months vs 37months)
  • FLOT better in all subgroups (benefit limited in N0).
  • What about CM577?

Oncology Brothers

5. LAURA:

  • Phase III, Indefinite Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
  • New SoC
  • Increase of PFS with Osi, 39.1 months vs 5.6 months (HR 0.16)
  • OS Pending –
  • 2 year PFS: 65% vs 13%
  • High cross over/received osi at progression
  • ≥Gr 3 AEs: 35% vs 12%

Oncology Brothers

6. ADRIATIC:

  • Phase III, durvalumab ± Tremi for 2 years after concurrent ChemoXRT limited stage small cell lung cancer
  • New SoC
  • Increase of OS with durva 55.9months vs 33.4 months (HR 0.73)
  • Increase of PFS (HR: 0.76)
  • Increase of AEs with Durvalumab

Oncology Brothers

7. ReachPC:

  • Role of Palliative Oncology using teleheath in Lung Cancer, n=1250
  • Collaboration with palliative oncology is critical
  • No QoL difference seen via telehealth or in person
  • Similar satisfaction by both means

Oncology Brothers

8. NADINA:

  • Phase III, n = 432, NeoAdj Ipi/Nivo vs. Adj Nivo in Stage III melanoma
  • New SoC
  • 1 year EFS: 83.7% vs 57.2%
  • Difference in restricted survival was 8 months (HR: 0.32)
  • 59% major path response
  • ≥Gr 3 AEs 29.7% with Ipi Nivo”

Oncology Brothers

Source: Oncology Brothers/X